Biosilicate® glass-ceramic (BioS) offers an attractive choice for the manufacturing of scaffolds because of their high bioactivity, non-toxicity, bactericidal activity and biodegradability. Despite these positive properties, Biosilicate® scaffolds that have been developed so far show low fracture strength, limiting their clinical application. For this reason, our aim was to increase their strength through vacuum infiltration of F18 bioactive glass. First, we calculated the maximum attainable theoretical compressive strength of a scaffold using the Ryshkewitch and Ashby-Gibson models. We show that for a total porosity of 80 %, σ₀ = 250 MPa, and n = 5 the compressive strength estimated by both models is approximately 4.5 MPa. Afterward, the Biosilicate scaffolds were prepared using the foam replica technique and recoated several times with a F18 glass slurry to eliminate surface defects. Scanning Electron Microscopy examination showed that the F18 indeed helped to remove surface defects and partially infiltrated the hollow struts, significantly increasing their mechanical integrity. The F18-BioS scaffolds exhibited a total porosity of 82 %, an average cell size of 525 μm, and compressive strength of 3.3 ± 0.3 MPa, which is close to the predicted value and significantly higher than those of sole BioS scaffolds of a similar structure (< 0.1 MPa). These values are within the range of commercial scaffolds based on Hydroxyapatite (HA) and β-tricalcium phosphate (β-TCP), having a considerable advantage of being more osteoinductive, angiogenic, and highly bactericidal. The F18-BioS scaffolds developed in this work thus have high potential for odontology or craniofacial surgeries that do not involve high load–bearing conditions.

生物硅酸盐玻璃陶瓷 (BioS) 因其高生物活性、无毒、杀菌活性和生物降解性，为支架制造提供了一个有吸引力的选择。尽管有这些积极的特性，但迄今为止开发的生物硅酸盐支架显示出较低的断裂强度，限制了它们的临床应用。出于这个原因，我们的目标是通过 F18 生物活性玻璃的真空渗透来增加它们的强度。首先，我们使用 Ryshkewitch 和 Ashby-Gibson 模型计算了支架可达到的最大理论抗压强度。我们表明，对于 80 % 的总孔隙率，σ ₀= 250 MPa，且 n = 5，两种模型估计的抗压强度约为 4.5 MPa。然后，使用泡沫复制技术制备生物硅酸盐支架，并用 F18 玻璃浆重新涂覆几次以消除表面缺陷。扫描电子显微镜检查表明，F18 确实有助于去除表面缺陷并部分渗入空心支柱，显着提高了它们的机械完整性。F18-BioS 支架的总孔隙率为 82%，平均细胞大小为 525 μm，抗压强度为 3.3 ± 0.3 MPa，接近预测值并显着高于类似结构的唯一 BioS 支架(< 0.1 兆帕)。这些值在基于羟基磷灰石 (HA) 和 β-磷酸三钙 (β-TCP) 的商业支架的范围内，具有更强的骨诱导性、血管生成性和杀菌性的显着优势。因此，在这项工作中开发的 F18-BioS 支架在不涉及高承载条件的牙病学或颅面手术中具有很高的潜力。